HIV-1 envelope determinants for cell tropism and chemokine receptor use.
about
Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milkHIV-1 envelope-receptor interactions required for macrophage infection and implications for current HIV-1 cure strategiesStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setSensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptorProbing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries.Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissuesA V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.HIV-1 Transmission, Replication Fitness and Disease Progression.Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Antigenically distinct conformations of CXCR4.Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system.Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-FcCoreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.Molecular machinations: chemokine signals in host-pathogen interactionsMolecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.V3-independent competitive resistance of a dual-X4 HIV-1 to the CXCR4 inhibitor AMD3100Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.Diversity of HIV type 1 envelope (V3-V5) sequence in HIV type 1-infected Indian children.Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.Characterization of a dual-tropic human immunodeficiency virus (HIV-1) strain derived from the prototypical X4 isolate HXBc2.Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain.The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assayEvolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
P2860
Q24598653-AF768E39-DA5C-4E70-8D1D-C029A7EBFC3DQ26825087-0F04065B-093E-4730-A3C5-88FD64766DB5Q27650903-C674028E-DC7C-449B-8B6F-0645BE4D3CB8Q28346124-4AAA6A3A-0AC4-498F-9127-EEC9C48FEB02Q33210857-A3C23181-F83B-4DCE-AE01-DA5F0F5EC060Q33218075-27D1A7CF-52C7-4F70-B165-9BD340229B7FQ33570314-C6B586E6-79CC-42D9-9217-3DF5255A5042Q33725702-9359FF14-1794-421C-B49A-A44DA705CEFCQ33758570-04F9F0DF-EEDC-4381-A35E-AB7B5B556BDEQ33797964-D0A208C6-37AA-4558-9B5B-828CFB125F64Q33804016-496EC242-CBE6-4531-94CC-8B4538231935Q33812812-C8728EEC-E926-4230-9ECE-03D4CF356D3DQ33845055-7C4E9A8F-6EB3-41C2-B5AE-927D39065784Q33850041-507B4275-192D-4AC0-8C61-26816F47447DQ33984231-0F39131B-ADD9-42FC-BFA3-678740D35B54Q34342429-F6A22742-7A4B-4213-81BD-0917332954B5Q34390819-81C4DAB5-67C7-4F80-8AF7-37B2283DE630Q34471322-5B345B5A-B26E-4F2E-BE1A-E5E8A224AA3CQ34503200-B53BA6B3-9DB4-4A86-BAC0-BCA656918C3DQ34558508-A274FA08-F5D2-4525-8B11-DFED748732BAQ34611466-821A951B-3FED-472C-8DD3-131A7B581755Q34781878-CCA6DD18-ECDF-41DF-A5AC-12F194253746Q35052934-DF53F9AD-85D1-4526-8B62-2E000C5B3CBDQ35107518-940FE566-4EDB-4B4A-8580-4B8BC2244F75Q35182388-AE14D743-2103-4DFF-9FC1-4AE346C7E960Q35859926-A6DFF71F-B5F1-4497-B610-711D695DF226Q35904487-FF42862D-106C-4BED-AE43-EC323BC71135Q36191170-5106D528-1430-4E10-9E4F-4EC87FA13536Q36424584-A66A32F8-33BD-4788-8B25-19581B94535EQ36476641-15EEE0F0-333E-4268-A47F-A5F0DB91C8ABQ36509765-3E6AB5CD-F83D-45F6-87C5-C0E6504E8B92Q36674792-12D656EF-D10D-4FB2-8988-9A4F7BACD9F7Q37145319-B652CEF4-C226-4439-AF17-DCD1D6294C2DQ37191794-BD20840C-1F16-4D96-AE2F-9BD7C6FD2784Q37747105-2BDA4654-CF8C-485B-9279-FF432FAC81D2Q38610610-1879938A-520F-46CD-8AE0-663FB3D0B8C7Q39094162-FB4EB004-5A63-47CC-8AFF-7022837E8256Q39227445-AAF47851-1E8A-452E-B76C-5BD18434E981Q39601180-87E222D7-CE45-4C20-ACDD-143DA19C325DQ39602915-D71CBA16-153F-47AB-AD2A-24B5E688AB95
P2860
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@ast
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@en
type
label
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@ast
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@en
prefLabel
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@ast
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@en
P2860
P356
P1476
HIV-1 envelope determinants for cell tropism and chemokine receptor use.
@en
P2093
P2860
P356
10.1080/096876899294760
P577
1999-01-01T00:00:00Z